These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 34292499

  • 1. Combination Therapy with KRAS and P38α siRNA Suppresses Colorectal Cancer Growth and Development in SW480 Cell Line.
    Kamran S, Seyedrezazadeh E, Shanehbandi D, Asadi M, Zafari V, Shekari N, Namvar L, Zarredar H.
    J Gastrointest Cancer; 2022 Sep; 53(3):597-604. PubMed ID: 34292499
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate.
    Wong CC, Qian Y, Li X, Xu J, Kang W, Tong JH, To KF, Jin Y, Li W, Chen H, Go MY, Wu JL, Cheng KW, Ng SS, Sung JJ, Cai Z, Yu J.
    Gastroenterology; 2016 Nov; 151(5):945-960.e6. PubMed ID: 27451147
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
    Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG.
    Clin Cancer Res; 2012 Feb 15; 18(4):1051-62. PubMed ID: 22173548
    [Abstract] [Full Text] [Related]

  • 6. Mediatory role of BLT2 in the proliferation of KRAS mutant colorectal cancer cells.
    Park J, Jang JH, Kim JH.
    Biochim Biophys Acta Mol Cell Res; 2019 Mar 15; 1866(3):329-336. PubMed ID: 30553812
    [Abstract] [Full Text] [Related]

  • 7. [Abnormal expression of APRIL in colorectal cancer cells promotes tumor growth and metastasis].
    Wang GH, Lu MH, Wang JC, Wang F, Ding WF, Wang YG, Ju SQ, Wang HM.
    Zhonghua Zhong Liu Za Zhi; 2013 Apr 15; 35(4):249-55. PubMed ID: 23985251
    [Abstract] [Full Text] [Related]

  • 8. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.
    Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX.
    World J Gastroenterol; 2019 Feb 21; 25(7):808-823. PubMed ID: 30809081
    [Abstract] [Full Text] [Related]

  • 9. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
    Cheon SK, Kim HP, Park YL, Jang JE, Lim Y, Song SH, Han SW, Kim TY.
    Mol Oncol; 2018 Aug 21; 12(8):1398-1409. PubMed ID: 29896883
    [Abstract] [Full Text] [Related]

  • 10. Requirement for epithelial p38α in KRAS-driven lung tumor progression.
    Vitos-Faleato J, Real SM, Gutierrez-Prat N, Villanueva A, Llonch E, Drosten M, Barbacid M, Nebreda AR.
    Proc Natl Acad Sci U S A; 2020 Feb 04; 117(5):2588-2596. PubMed ID: 31969449
    [Abstract] [Full Text] [Related]

  • 11. Combination therapy with KRAS siRNA and EGFR inhibitor AZD8931 suppresses lung cancer cell growth in vitro.
    Zarredar H, Pashapour S, Ansarin K, Khalili M, Baghban R, Farajnia S.
    J Cell Physiol; 2019 Feb 04; 234(2):1560-1566. PubMed ID: 30132854
    [Abstract] [Full Text] [Related]

  • 12. Exploring the Therapeutic Potential of Fe3O4@Glu-Oleuropein Nanoparticles in Targeting KRAS Pathway-Regulating lncRNAs in Colorectal Cancer Cells.
    Mahdavi Niyaki Z, Salehzadeh A, Peymani M, Zaefizadeh M.
    Biol Trace Elem Res; 2024 Jul 04; 202(7):3073-3085. PubMed ID: 37792268
    [Abstract] [Full Text] [Related]

  • 13. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T.
    Theranostics; 2020 Jul 04; 10(11):5107-5119. PubMed ID: 32308771
    [Abstract] [Full Text] [Related]

  • 14. Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
    Valentino JD, Elliott VA, Zaytseva YY, Rychahou PG, Mustain WC, Wang C, Gao T, Evers BM.
    Surgery; 2012 Aug 04; 152(2):277-85. PubMed ID: 22828149
    [Abstract] [Full Text] [Related]

  • 15. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 16. Downregulation of miR‑143 modulates KRAS expression in colorectal carcinoma cells.
    Liu H, Liu J, Huo J, Li K, Li K, Guo H, Yang Y.
    Oncol Rep; 2019 Dec 20; 42(6):2759-2767. PubMed ID: 31638218
    [Abstract] [Full Text] [Related]

  • 17. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 18. Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38α siRNA in Lung Adenocarcinoma Cancer Cells.
    Zarredar H, Farajnia S, Ansarin K, Baradaran B, Aria M, Asadi M.
    Anticancer Agents Med Chem; 2019 Jul 14; 19(5):638-644. PubMed ID: 30827261
    [Abstract] [Full Text] [Related]

  • 19. Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers.
    Fernandes MS, Melo S, Velho S, Carneiro P, Carneiro F, Seruca R.
    Oncotarget; 2016 Oct 18; 7(42):68546-68558. PubMed ID: 27602501
    [Abstract] [Full Text] [Related]

  • 20. Cordyceps militaris Grown on Germinated Soybean Suppresses KRAS-Driven Colorectal Cancer by Inhibiting the RAS/ERK Pathway.
    Seo H, Song J, Kim M, Han DW, Park HJ, Song M.
    Nutrients; 2018 Dec 21; 11(1):. PubMed ID: 30577618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.